XML 37 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net loss $ (28,650) $ (28,177)
Adjustment to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 665 168
Gain on sale of marketable securities 0 1,392
Deferred taxes 0 (63)
Non-cash stock-based compensation 4,435 1,344
Fair value of common stock warrants issued in exchange for services    8,238
Change in fair value of common stock warrants (13,174) 7,135
Change in fair value of contingent consideration 59 559
Changes in operating assets and liabilities:    
Accounts receivable 2,248 (1,543)
Inventories (64) (425)
Prepaid expenses and other assets (363) 68
Accounts payable 700 (86)
Accrued expenses and other current liabilities 2,018 1,975
Net cash used in operating activities (32,126) (20,437)
Cash flows from investing activities:    
Change in restricted cash 0 1
Cash paid for acquisition of GALE-401 rights (2,315) 0
Proceeds from sale of marketable securities 0 1,392
Cash paid for purchase of equipment and furnishings (48) (554)
Net cash used in investing activities (5,419) (9,236)
Cash flows from financing activities:    
Net proceeds from issuance of common stock    37,520
Net proceeds from exercise of common stock options 4,342 9
Net proceeds from exercise of common stock warrants 10,717 820
Proceeds from common stock issued in connection with ESPP 263 69
Net proceeds from issuance of long-term debt 0 9,865
Principle payments on long-term debt (908) 0
Repayments of capital lease obligations (9) (21)
Net cash provided by financing activities 14,405 48,262
Net increase (decrease) in cash and cash equivalents (23,140) 18,589
Cash and cash equivalents at the beginning of period 47,787 32,807
Cash and cash equivalents at end of period 24,647  
Supplemental disclosure of cash flow information:    
Cash received during the periods for interest 13  
Cash paid during the periods for interest 632 195
Supplemental disclosure of non-cash investing and financing activities:    
Reclassification of warrant liabilities upon exercise (27,026) (2,070)
Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone 0 1,000
Change in fair value of marketable securities 0 1,551
Abstral [Member]
    
Cash flows from investing activities:    
Cash paid for acquisition of Abstral rights 0 (10,075)
Supplemental disclosure of non-cash investing and financing activities:    
Future payment for Abstral rights included in accrued expenses 0 5,000
Zuplenz [Member]
    
Cash flows from investing activities:    
Cash paid for acquisition of Abstral rights (3,056) 0
Supplemental disclosure of non-cash investing and financing activities:    
Future payment for Abstral rights included in accrued expenses $ 4,607